Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Drug or technology

Osimertinib + Chemotherapy

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 9, 2026 · OBSERVATIONAL STUDY

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

ClinicalTrials.gov

This is a registry record for an active observational study with no results posted; it describes planned enrollment and methods only, without outcome data.

PreliminaryOsimertinib + Chemotherapy Osimertinib PrECOG

Reported

Planned enrollment200

Primary outcome measurereal-world Progression-Free Survival (rwPFS…

Study typeObservational

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support